pharma
Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
October 17, 2019Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
Medical cannabis: Riding the wave
October 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma
Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …
Alexion to acquire Achillion Pharma for $930 million
October 16, 2019Research and Development, Sales and Marketing Alexion, achillion, merger, pharma
Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
China approves Eisai’s Fycompa for partial onset epileptic seizures
October 16, 2019Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma
Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
FDA approves first and only transdermal patch for schizophrenia
October 16, 2019Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia
Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
FDA approves Janssen’s Xarelto for blood clot prevention
October 15, 2019Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
Medical cannabis: On to greener pastures?
October 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma
In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
October 14, 2019Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
October 14, 2019Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
Biotechnology Innovation Organization Chief to step down after US 2020 elections
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma
The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
The Lung Ambition Alliance: Stronger together
October 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma
Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture
October 9, 2019Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma
The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
